Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis ; volume:19 ; number:1 ; day:8 ; month:4 ; year:2019 ; pages:1-11 ; date:12.2019
BMC gastroenterology ; 19, Heft 1 (8.4.2019), 1-11, 12.2019
- Creator
-
Pu, Ke
Wang, Yuping
Bai, Suyang
Wei, Hui
Zhou, Yongning
Fan, Jiangao
Qiao, Liang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-019-0961-9
- URN
-
urn:nbn:de:101:1-2019042800100468758861
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Pu, Ke
- Wang, Yuping
- Bai, Suyang
- Wei, Hui
- Zhou, Yongning
- Fan, Jiangao
- Qiao, Liang
- SpringerLink (Online service)
Other Objects (12)
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease